Clinical Trial Update: Study of CDX-3379, a Human Monoclonal Antibody Targeting ERBB3, in Combination With the MEK Inhibitor, Trametinib, in Patients With Advanced Stage NRAS Mutant and BRAF/NRAS Wildtype (WT) Melanoma [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial of CDX-3379 with trametinib in advanced NRAS-mutant or WT melanoma was terminated; no results posted in the snippet.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• CDX-3379 (CDX-3379)
• Trametinib (trametinib)

Snippet

Sponsor: NYU Langone Health | Conditions: Melanoma | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2020-05-20